Sotera Health Company (SHC)
| Market Cap | 5.35B +18.2% |
| Revenue (ttm) | 1.22B +8.1% |
| Net Income | 163.48M +580.5% |
| EPS | 0.57 +570.8% |
| Shares Out | 285.37M |
| PE Ratio | 33.19 |
| Forward PE | 18.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 137,410 |
| Open | 18.77 |
| Previous Close | 18.55 |
| Day's Range | 18.68 - 18.98 |
| 52-Week Range | 13.09 - 19.85 |
| Beta | 1.86 |
| Analysts | Buy |
| Price Target | 22.72 (+21.11%) |
| Est. Earnings | Nov 3, 2026 |
About SHC
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion seg... [Read more]
Financial Performance
In 2025, Sotera Health Company's revenue was $1.16 billion, an increase of 5.74% compared to the previous year's $1.10 billion. Earnings were $77.95 million, an increase of 75.79%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SHC stock is "Buy." The 12-month stock price target is $22.72, which is an increase of 21.11% from the latest price.
News
Sotera Health Company Transcript: Wells Fargo 21st Annual Healthcare Conference
The event highlighted strong growth and operational stability across all business units, with integrated offerings and customer focus driving performance. Margin expansion, robust cash flow, and disciplined capital allocation support future investments, while regulatory and geopolitical risks remain limited.
Sotera Health price target raised to $25 from $23 at Citi
Citi raised the firm’s price target on Sotera Health (SHC) to $25 from $23 and keeps a Buy rating on the shares.
Sotera Health price target raised to $22 from $19 at Barclays
Barclays raised the firm’s price target on Sotera Health (SHC) to $22 from $19 and keeps an Overweight rating on the shares post the Q2 report. Sterigenics came in above…
Sotera Health Company Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue and margin growth across all segments, prompting an increased full-year outlook for revenue, EBITDA, and EPS. Key drivers included robust Sterigenics and Nordion performance, new X-ray capacity, and a major customer outsourcing shift.
Sotera Health Company Earnings release: Q2 2026
Sotera Health Company released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Sotera Health Company Slides: Q2 2026
Sotera Health Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Sotera Health Company Quarterly report: Q2 2026
Sotera Health Company has published its Q2 2026 quarterly earnings report on August 6, 2026.
Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis (1) compared to Q2 2025 Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $...
Sotera Health Announces Second-Quarter 2026 Earnings Release Date
CLEVELAND, July 23, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services fo...
Sotera Health price target raised to $19 from $18 at Barclays
Barclays raised the firm’s price target on Sotera Health (SHC) to $19 from $18 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
Sotera Health Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Leadership transition is underway with a new CEO set for 2026, while strong Q1 growth and margin expansion were reported. Regulatory compliance investments and litigation outcomes are shaping the outlook, with capacity expansions and M&A focused on Sterigenics and global growth.
Sotera Health initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Sotera Health (SHC) with a Buy rating and $20 price target Sotera is a provider of sterilization and lab testing services, serving 40 of the…
Sotera Health Company Transcript: Jefferies Global Healthcare Conference 2026
A planned CEO transition brings new leadership with continuity in strategy and growth focus. Business segments show resilience and recovery, with supply chain investments and cross-selling initiatives supporting future performance. Litigation and financial outlook remain stable and well-managed.
Sotera Health Company Transcript: AGM 2026
The meeting covered board updates, strong financial growth, and approval of all proposals, including director elections, executive compensation, and auditor ratification. Strategic focus remains on integrated healthcare solutions and sustained above-market growth.
Sotera Health Company Transcript: RBC Capital Markets Global Healthcare Conference 2026
Leadership transition brings a new CEO with strong med device experience. Sterigenics and Nelson Labs segments show robust demand and margin recovery, supported by new capacity and regulatory-driven growth. Legal wins and a broadened shareholder base position the company for continued momentum.
Sotera Health announces offering of 31.84M shares of common stock for holders
Sotera Health (SHC) Company announced the launch of a secondary offering of 31.84M shares of its common stock. All 31.84M shares are being offered for sale by certain affiliates of…
Sotera Health Announces Secondary Offering of Common Stock
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common s...
Sotera Health price target lowered to $22 from $24 at Piper Sandler
Piper Sandler analyst Jason Bednar lowered the firm’s price target on Sotera Health (SHC) to $22 from $24 and keeps an Overweight rating on the shares. The firm notes the…
Sotera Health names Alton Shader as CEO
Sotera Health (SHC) announced the appointment of Alton Shader to the role of CEO of the company, effective May 26, as part of a planned leadership transition. Shader will succeed…
Sotera Health Company Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% revenue growth and 10.5% Adjusted EBITDA growth, with margin expansion and strong segment performance, especially in Nordion. The 2026 outlook was reaffirmed, a CEO transition was announced, and all Georgia bellwether legal cases were dismissed.
Sotera Health Company Earnings release: Q1 2026
Sotera Health Company released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Sotera Health Company Slides: Q1 2026
Sotera Health Company has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Sotera Health Company Quarterly report: Q1 2026
Sotera Health Company has published its Q1 2026 quarterly earnings report on May 5, 2026.
Sotera Health Company Proxy statement: Proxy filing
Sotera Health Company filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Q1 2026 net revenues increased 10.0%, or 6.5% on a co nstant currenc y basis, compared to Q1 2025 Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or...